Search results
13 lis 2017 · In addition, blood eosinophilia has been associated with positive response to immunotherapy and is generally correlated with longer survival in advanced melanoma patients, 125–127 whereas it is an unfavorable prognostic factor in T-cell leukemia/lymphoma. 128 These apparently conflicting results are intriguing and suggest that the role of ...
20 gru 2023 · Eosinophilia is a common feature of certain blood cancers, such as eosinophilic leukemia and Hodgkin lymphoma, as well as solid tumor cancers of the colon, lungs, breast, and others. This article describes the function of eosinophils and the conditions associated with eosinophilia.
Risk Stratification: Disease prognosis relies on identifying the subtype of eosino- philia. After evaluation of secondary causes of eosinophilia, the 2016 World Health Organization endorses a semi-molecular classification scheme of disease subtypes.
9 gru 2022 · Given the broad differential diagnosis of HES, a comprehensive approach is needed to identify potential secondary (treatable) causes and define end-organ manifestations. Classification by clinical HES subtype is also useful in terms of assessing prognosis and guiding therapy.
27 sie 2015 · Because systemic corticosteroids remain the first-line therapy for most forms of HES, identification of patients with (1) secondary eosinophilia requiring specific therapy directed at the underlying etiology (associated HES), (2) PDGFRA-positive MPN or other steroid-resistant eosinophilic myeloproliferative disorders, and (3) overlap syndromes ...
15 wrz 2021 · The identification of clinically useful biomarkers to aid in diagnosis, prognosis, and treatment decisions in EGPA and HES is required, as is additional investigation into factors affecting their clinical presentation. 1 In particular, cardiac disease and thrombophilia can be serious complications in HES, 63 although they do not affect all ...
5 gru 2015 · Clinical manifestations range from benign asymptomatic presentations to life-threatening complications, including endomyocardial fibrosis and thromboembolism. The prognosis and choice of treatment depend not only on the degree of eosinophilia and severity of organ involvement, but also on the etiology of the eosinophilia.
